Breaking News

Financial Report: Bristol-Myers Squibb

January 24, 2013

Avapro, Plavix patent expirations hurt results

Bristol-Myers Squibb
4Q Revenues: $4.2 billion (-23%)

4Q Earnings: $924 million (-25%)

YTD Revenues: $17.6 billion (-17%)

YTD Earnings: $2.5 billion (-52%)

Comments: U.S. sales decreased 38% to $2.2 billion in the quarter due to patent expirations for Avapro/Avalide in March 2012 and Plavix in May 2012. International sales were up 6% to $2.0 billion. Plavix sales were down 97% to $49 million. Avapro/Avalide sales were down 57% to $84 million. Abilify sales were up 11% to $819 million. Sprycel sales were up 24% to $281 million. Yervoy sales were up 47% to $211 million. Orencia sales were up 26% to $325 million. Onglyza/Kombiglyze sales were $198 million, up 29%. R&D expenses increased 7% to $1.1 billion in the quarter.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks